Fundraising Fox
/Companies
Sign in

AllTrna

Founded 2018 · 43 employees on LinkedIn · 1 known investors

Find your way into AllTrna

Sign up to see every warm intro you have to AllTrna

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AllTrna team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.

AI & Machine LearningBiotechDeep TechHealthtech

Founders & leadership

AllTrna was founded in 2018 by Lovisa Afzelius.

LALovisa Afzelius
Lovisa AfzeliusExecutive Chair & Founding CEOLovisa Afzelius is a general partner at Flagship Pioneering with two decades of leadership experience across biotech and pharmaceutical companies, including CEO and board positions. She holds a background in computational science and has worked on data-driven drug discovery programs spanning early development through clinical stages across multiple therapeutic areas.
MWMichelle Werner
Michelle WernerCEOMichelle Werner is CEO of AllTrna, which develops engineered tRNA oligonucleotides as programmable medicines for treating genetic diseases. She has prior commercial experience in the pharmaceutical industry across sales, marketing, and business planning.
JPJoanne Protano
Joanne ProtanoPresident & Chief Financial OfficerExecutive Officer at Rubius Therapeutics
DHDave Hava
Dave HavaChief Scientific OfficerHe has spent 20 years in biotech leadership roles, including 14 years as CSO or Head of R&D at public and private companies, with expertise in translating therapeutic platforms from early-stage research to clinical development across rare metabolic diseases, oncology, inflammatory diseases, and nucleic acid therapies. He holds training in microbiology and immunology.
NKNerissa Kreher
Nerissa KreherChief Medical OfficerNerissa Kreher is a board-certified pediatric endocrinologist with experience spanning academic medicine, clinical research, and biotech industry roles in medical affairs and clinical development. She holds an MBA and specializes in rare disease strategy.
CKCaroline Köhrer
Caroline KöhrerSVP, Discovery Platform

Investors · 1

Founder mafia

2 people who came through AllTrna went on to found or lead other companies.

Noubar AfeyanFounding ChairmanFounded ProFound Therapeutics +16Austin DraycottConsultantFounded Cloverleafbio

Frequently asked questions

What does AllTrna do?
Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.
Who founded AllTrna?
AllTrna was founded by Lovisa Afzelius in 2018.
Who are AllTrna's investors?
AllTrna's investors include Flagship Pioneering.